Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
On World AIDS Day 2025, Africa launched lenacapavir, a highly effective twice-yearly HIV prevention injection, amid funding shortfalls threatening access.
On World AIDS Day 2025, South Africa, Eswatini, and Zambia began rolling out lenacapavir, a twice-yearly injectable HIV prevention drug with over 99.9% effectiveness, marking the first public use in Africa.
Approved by WHO in October 2025, the long-acting pre-exposure prophylaxis (PrEP) offers a critical alternative to daily pills, improving adherence and reducing stigma.
Gilead Sciences is providing the drug at no profit to two million people in low- and middle-income countries over three years, with generic versions expected by 2027.
Despite this progress, international funding cuts have disrupted HIV services, leaving an estimated 2.5 million people without PrEP access.
WHO warns that sustained investment and equitable access are essential to achieving the 2030 goal of ending AIDS.
En el Día Mundial del SIDA 2025, África lanzó lenacapavir, una inyección de prevención del VIH dos veces al año altamente efectiva, en medio de la escasez de fondos que amenaza el acceso.